By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Scancell, Ltd. 

P.O. Box 6457

Nottingham    NG5 1QA  United Kingdom
Phone: 44-0-115-962-8033 Fax: +44-0-115-962-8033



Company News
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015 11:21:26 AM
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014 10:35:20 AM
Scancell To Present At Upcoming Scientific Conferences 9/12/2014 10:15:49 AM
Scancell Release: Final Results For The Year Ended 30 April 2014 9/4/2014 2:39:25 PM
Scancell Release: Synergy Of SCIB1 With Checkpoint Inhibitors 8/12/2014 12:42:52 PM
Scancell: DNA ImmunoBody Patent Granted In United States 6/6/2014 10:47:58 AM
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014 10:24:57 AM
Scancell To Present SCIB1 At American Association for Cancer Research Annual Meeting 4/4/2014 10:58:14 AM
Scancell: 8mg Higher Dose SCIB1 Study On Track 3/21/2014 9:36:40 AM
Scancell: Publication Of Moditope Patent 2/18/2014 8:59:05 AM